已入深夜,您辛苦了!由于当前在线用户较少,发布求助请尽量完整的填写文献信息,科研通机器人24小时在线,伴您度过漫漫科研夜!祝你早点完成任务,早点休息,好梦!

No genetic associations with mepolizumab efficacy in COPD with peripheral blood eosinophilia

医学 美波利祖马布 慢性阻塞性肺病 嗜酸性粒细胞增多症 内科学 逻辑回归 析因分析 基因检测 嗜酸性粒细胞 物理疗法 免疫学 哮喘
作者
Lynn D. Condreay,Chuan Gao,Eric Bradford,Steven W. Yancey,Soumitra Ghosh
出处
期刊:Respiratory Medicine [Elsevier]
卷期号:155: 26-28 被引量:6
标识
DOI:10.1016/j.rmed.2019.07.004
摘要

IntroductionImproved understanding of genetic effects on response to treatments with novel approaches for COPD with peripheral blood eosinophilia, such as mepolizumab (a humanized monoclonal antibody to IL-5), may improve treatment outcomes. We conducted a study to identify genetic variants associated with efficacy of mepolizumab COPD.Materials and methodsUsing generalized linear and logistic regression models, genome-wide association analyses were performed to investigate genetic associations with frequency of moderate and/or severe COPD exacerbations in COPD subjects receiving mepolizumab (weeks 0–52). Additional analyses included: (i) frequency of COPD exacerbations requiring hospitalization or emergency department visit (weeks 0–52), (ii) change from baseline mean total St. George's Respiratory Questionnaire (SGRQ) score (week 24), and (iii) SGRQ response defined as achieving a 4 unit or greater decrease of SGRQ score from baseline (week 24). This study included 610 patients with COPD, a subset of the Intent-to-treat (ITT) populations in two phase III double-blind trials assessing the efficacy and safety of mepolizumab, METREX (NCT02105948) and METREO (NCT02105961). All subjects had elevated eosinophil levels (≥150 cells/μL at screening or ≥300 cell/μL in the 12 months prior to study), were treated with mepolizumab, and provided consent for genetic analysis.ResultsFrom this post-hoc analysis, no genetic variant was significantly associated with moderate and/or severe COPD exacerbations or any of the other endpoints tested (threshold for statistical significance at the genome-wide level, p = 5 × 10−8).ConclusionsIn this exploratory study in patients with COPD, with peripheral blood eosinophilia, no genetic effects on mepolizumab-treatment response were identified.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
大幅提高文件上传限制,最高150M (2024-4-1)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
刚刚
2秒前
cuidalice发布了新的文献求助20
3秒前
3秒前
liway完成签到 ,获得积分10
4秒前
Xxi发布了新的文献求助10
5秒前
动听千山发布了新的文献求助10
6秒前
秀丽的咖啡完成签到,获得积分10
6秒前
7秒前
沉小墨发布了新的文献求助30
9秒前
嗝嗝发布了新的文献求助10
9秒前
lzl完成签到,获得积分10
9秒前
Mrshi发布了新的文献求助10
11秒前
11秒前
sxc110完成签到,获得积分10
14秒前
杉进完成签到 ,获得积分10
14秒前
15秒前
16秒前
科研通AI2S应助小面包狗采纳,获得10
16秒前
巫万声发布了新的文献求助10
17秒前
伶俐断天发布了新的文献求助10
17秒前
WJ发布了新的文献求助10
20秒前
顾矜应助Mrshi采纳,获得10
21秒前
俗人应助KK采纳,获得10
22秒前
科研通AI2S应助伶俐断天采纳,获得10
24秒前
xx完成签到 ,获得积分10
25秒前
28秒前
司徒恋风发布了新的文献求助10
31秒前
somnus_fu完成签到,获得积分10
32秒前
33秒前
zzbbzz完成签到,获得积分20
33秒前
慕青应助树叶有专攻采纳,获得10
36秒前
zzbbzz发布了新的文献求助30
37秒前
37秒前
Hello应助专注的月亮采纳,获得10
38秒前
科研通AI2S应助刘笨笨采纳,获得10
40秒前
ljh完成签到 ,获得积分10
40秒前
40秒前
41秒前
liqin_wu完成签到,获得积分20
42秒前
高分求助中
歯科矯正学 第7版(或第5版) 1004
The diagnosis of sex before birth using cells from the amniotic fluid (a preliminary report) 1000
Smart but Scattered: The Revolutionary Executive Skills Approach to Helping Kids Reach Their Potential (第二版) 1000
Semiconductor Process Reliability in Practice 720
GROUP-THEORY AND POLARIZATION ALGEBRA 500
Mesopotamian divination texts : conversing with the gods : sources from the first millennium BCE 500
Days of Transition. The Parsi Death Rituals(2011) 500
热门求助领域 (近24小时)
化学 医学 生物 材料科学 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 基因 遗传学 催化作用 物理化学 免疫学 量子力学 细胞生物学
热门帖子
关注 科研通微信公众号,转发送积分 3229546
求助须知:如何正确求助?哪些是违规求助? 2877143
关于积分的说明 8198010
捐赠科研通 2544488
什么是DOI,文献DOI怎么找? 1374437
科研通“疑难数据库(出版商)”最低求助积分说明 646970
邀请新用户注册赠送积分活动 621749